NEW YORK ( TheStreet) -- As the most fraught influenza season since 1918 moves toward its Northern Hemisphere opening day, one outcome is perhaps more certain than any other: The hysteria surrounding the stocks of certain biotech firms will fade like summer itself.
Ever since swine flu entered the lexicon back in April, a kind of mini-bubble has developed in the shares of companies claiming to have an H1N1 fix, and that bubble seems primed to pop.
More than a few developers of antiviral drugs have seen their stocks explode on little to no evidence that their treatments have any near-term commercial prospects ( see: Biocryst (BCRX)). But the case for the bubble's imminent deflation is even clearer among those companies attempting to develop novel influenza vaccines.
Traders, speculators and presumably buy-and-hold investors have piled into these shares. (Early-stage biotech, no matter the specific field, has always been closer to gambling than investing, after all.) Novavax (NVAX), a Rockville, Md.-based vaccine specialist, has seen its stock price increase 217% since Jan. 1 -- a relative laggard. Shares of Vical (VICL), a San Diego vaccine developer, have gained 256% over the same period, while Inovio (INO), also of San Diego, has exploded by 285% and Hemispherix (HEB), which has promoted its much-delayed chronic-fatigue treatment as a swine-flu-vaccine booster, has grown by a whopping 478%.Needless to say, these stocks have outperformed the broader market. The reason? Press releases by the bale, issued over the last five months touting this or that new study in which some new approach to flu vaccines has shown signs of not only besting the traditional vaccine methods, but of profiting big from any potential swine-flu plague.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV